

# Andrea Gaetano Allegra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/530861/publications.pdf>

Version: 2024-02-01

18  
papers

413  
citations

759233

12  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. <i>Mediators of Inflammation</i> , 2017, 2017, 1-24.	3.0	99
2	Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. <i>Annals of Hematology</i> , 2020, 99, 1953-1965.	1.8	54
3	Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. <i>Annals of Hematology</i> , 2018, 97, 1259-1269.	1.8	44
4	Nanobodies and Cancer: Current Status and New Perspectives. <i>Cancer Investigation</i> , 2018, 36, 221-237.	1.3	28
5	Therapeutic potential of antagomiRs in haematological and oncological neoplasms. <i>European Journal of Cancer Care</i> , 2020, 29, e13208.	1.5	23
6	Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2822.	4.1	21
7	Formaldehyde Exposure and Acute Myeloid Leukemia: A Review of the Literature. <i>Medicina (Lithuania)</i> , 2019, 55, 638.	2.0	18
8	Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw. <i>BioMed Research International</i> , 2020, 2020, 1-10.	1.9	15
9	The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention. <i>European Journal of Internal Medicine</i> , 2018, 53, 12-20.	2.2	14
10	Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 689-698.	0.4	14
11	Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma. <i>Cells</i> , 2021, 10, 439.	4.1	14
12	Relationship between mitofusin 2 and cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2019, 116, 209-236.	2.3	13
13	Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology. <i>Expert Review of Hematology</i> , 2020, 13, 393-404.	2.2	13
14	Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma. <i>Antioxidants</i> , 2019, 8, 55.	5.1	12
15	Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs. <i>Current Oncology</i> , 2021, 28, 159-183.	2.2	11
16	SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma. <i>Clinical Biochemistry</i> , 2021, 93, 42-49.	1.9	9
17	Changes in Serum Interleukin-8 and sRAGE Levels in Multiple Myeloma Patients. <i>Anticancer Research</i> , 2020, 40, 1443-1449.	1.1	8
18	Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma. <i>Archives of Medical Science</i> , 2021, 18, 696-703.	0.9	3